ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$3.48
0.17 (5.14%)
▲
5d:
-14.29%
30d:
-17.92%
90d:
-21.97%
WAIT
LOW Confidence
Analysis Updated: Feb 6, 2026 12:00 AM ET
Earnings: Feb 04, 2026
0d
Smart Money Accumulation
ACB is down 8.4% this week, but smart money is accumulating calls. Top strike: $6 2026-03-20 with 2,939 OI. Call ratio: 60% View Scanner →
Strength: 5.2/10
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called ACB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ACB is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ACB is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $3.48, which is considered oversold relative to its 30-day fair value range of $3.90 to $4.42. From a valuation perspective, the stock is trading at a discount (Forward PE: -107.1) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a downtrend. Immediate support is located at $3.28, while resistance sits at $4.47. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: ACB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.37 (+83.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACB is in a downtrend. Immediate support is located at $3.28, while resistance sits at $4.47. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: ACB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.37 (+83.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.90 -
$4.42
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
Protect Your Profits
Holding ACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 83.1% below Wall St target ($6.37)
- WARNING: Recommendation downgraded due to -14.3% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$3.90 -
$4.42
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.28
Resistance Level
$4.47
Current Trend
Downtrend
Technical data as of
Feb 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-107.08
Wall Street Target
$6.37
(+83.1%)
Revenue Growth (YoY)
6.8%
Earnings Growth (YoY)
-95.2%
Profit Margin
-23.4%
PE vs Historical
-107.1 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: February 09, 2026 12:22 AM ET
Data refreshes hourly during market hours. Next update: 1:22 AM
Data refreshes hourly during market hours. Next update: 1:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 60 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 54 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$37 | 59 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
